{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:26:06Z","timestamp":1789025166432,"version":"build-2803163510"},"reference-count":32,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14114","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:15:26Z","timestamp":1698063326000},"source":"Crossref","is-referenced-by-count":19,"title":["Immunohistochemical expression of TROP\u20112 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer"],"prefix":"10.3892","volume":"26","author":[{"given":"Mahmoud","family":"Abbas","sequence":"first","affiliation":[{"name":"Department of Pathology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Heitplatz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Bernemann","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Trautmann","sequence":"additional","affiliation":[{"name":"Department of Pathology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Schrader","sequence":"additional","affiliation":[{"name":"Department of Pathology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[{"name":"Department of Pathology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University of Muenster Medical Center, D\u201148149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"key20231122104230_b1-ol-26-6-14114","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"key20231122104230_b2-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","article-title":"Urothelial carcinoma management in elderly or unfit patients","volume":"14","author":"Bellmunt","year":"2016","journal-title":"EJC Suppl"},{"key":"key20231122104230_b3-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.29387","article-title":"Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer","volume":"121","author":"Galsky","year":"2015","journal-title":"Cancer"},{"key":"key20231122104230_b4-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"317190","DOI":"10.1155\/2013\/317190","article-title":"Pathologic response rates of gemcitabine\/cisplatin versus methotrexate\/vinblastine\/adriamycin\/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer","volume":"2013","author":"Lee","year":"2013","journal-title":"Adv Urol"},{"key":"key20231122104230_b5-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"key20231122104230_b6-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"key20231122104230_b7-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"key20231122104230_b8-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20231122104230_b9-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20231122104230_b10-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20231122104230_b11-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20231122104230_b12-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"key20231122104230_b13-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.3390\/ijms21197268","article-title":"Targeted molecular therapeutics for bladder cancer-a new option beyond the mixed fortunes of immune checkpoint inhibitors?","volume":"21","author":"Bednova","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20231122104230_b14-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17925\/EE.2021.17.1.21","article-title":"Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies","volume":"17","author":"George","year":"2021","journal-title":"touchREV Endocrinol"},{"key":"key20231122104230_b15-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"key20231122104230_b16-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotinin previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"key20231122104230_b17-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecanin patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20231122104230_b18-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: Future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"Onco Targets Ther"},{"key":"key20231122104230_b19-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12885-017-3475-2","article-title":"Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways","volume":"17","author":"Guan","year":"2017","journal-title":"BMC Cancer"},{"key":"key20231122104230_b20-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via \u03b2-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev"},{"key":"key20231122104230_b21-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B","article-title":"Cloning of the murine Trop2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop-2","volume":"75","author":"El Sewedy","year":"1998","journal-title":"Int J Cancer"},{"key":"key20231122104230_b22-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"key20231122104230_b23-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.18632\/oncotarget.6733","article-title":"Trop2 is overexpressed in gastric cancer and predicts poor prognosis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"key20231122104230_b24-ol-26-6-14114","article-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016","edition":"8th edition"},{"key":"key20231122104230_b25-ol-26-6-14114","author":"WHO-Classification of urinary and male genital tumours","year":"2022","edition":"5th Edition"},{"key":"key20231122104230_b26-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"11547","DOI":"10.3390\/ijms222111547","article-title":"Evaluation of therapeutic targets in histological subtypes of bladder cancer","volume":"22","author":"Wucherpfennig","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20231122104230_b27-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: A tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"key20231122104230_b28-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr Oncol"},{"key":"key20231122104230_b29-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: Potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"key20231122104230_b30-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","article-title":"Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"key20231122104230_b31-ol-26-6-14114","first-page":"515","article-title":"Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells","volume":"53","author":"Zhang","year":"2018","journal-title":"Int J Oncol"},{"key":"key20231122104230_b32-ol-26-6-14114","doi-asserted-by":"publisher","first-page":"58642","DOI":"10.18632\/oncotarget.17407","article-title":"The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer","volume":"8","author":"Avellini","year":"2017","journal-title":"Oncotarget"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:48:17Z","timestamp":1700642897000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14114","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"527"}}